Is OCULAR THERAPEUTIX, INC (OCUL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.4% / 30% | 33.0% / 30% | 1.4% / 30% | 35.33% / 5% | ✗ NOT HALAL |
| DJIM | 3.4% / 33% | 33.0% / 33% | 1.4% / 33% | 35.33% / 5% | ✗ NOT HALAL |
| MSCI | 9.5% / 33% | 91.2% / 33% | 3.8% / 33% | 35.33% / 5% | ✗ NOT HALAL |
| S&P | 3.4% / 33% | 33.0% / 33% | 1.4% / 33% | 35.33% / 5% | ✗ NOT HALAL |
| FTSE | 9.5% / 33% | 91.2% / 33% | 3.8% / 50% | 35.33% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -292.0% | |
| Operating Margin | -526.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -54.9% | |
| Return on Assets (ROA) | -26.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$205M |
| Free Cash Flow | -$217M |
| Total Debt | $77M |
| Debt-to-Equity | 11.8 |
| Current Ratio | 15.4 |
| Total Assets | $808M |
Price & Trading
| Last Close | $8.07 |
| 50-Day MA | $9.29 |
| 200-Day MA | $11.11 |
| Avg Volume | 6.2M |
| Beta | 0.9 |
|
52-Week Range
$5.80
| |
About OCULAR THERAPEUTIX, INC (OCUL)
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is OCULAR THERAPEUTIX, INC (OCUL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), OCULAR THERAPEUTIX, INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is OCULAR THERAPEUTIX, INC's debt ratio?
OCULAR THERAPEUTIX, INC's debt ratio is 3.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.5%.
What are OCULAR THERAPEUTIX, INC's key financial metrics?
OCULAR THERAPEUTIX, INC has a market capitalization of $1.6B, and revenue of $52M. Return on equity stands at -54.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.